Cargando…

Surgical treatment of infective endocarditis in intravenous drug abusers

BACKGROUND: Despite current progress in antibiotic therapy and medical management, infective endocarditis remains a serious condition presenting with high mortality rates. It also is a life-threatening complication in patients with a history of chronic intravenous drug abuse. In this study, we analy...

Descripción completa

Detalles Bibliográficos
Autores principales: Zubarevich, Alina, Szczechowicz, Marcin, Osswald, Anja, Easo, Jerry, Rad, Arian Arjomandi, Vardanyan, Robert, Schmack, Bastian, Ruhparwar, Arjang, Zhigalov, Konstantin, Weymann, Alexander
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8056573/
https://www.ncbi.nlm.nih.gov/pubmed/33879196
http://dx.doi.org/10.1186/s13019-021-01491-1
_version_ 1783680675244670976
author Zubarevich, Alina
Szczechowicz, Marcin
Osswald, Anja
Easo, Jerry
Rad, Arian Arjomandi
Vardanyan, Robert
Schmack, Bastian
Ruhparwar, Arjang
Zhigalov, Konstantin
Weymann, Alexander
author_facet Zubarevich, Alina
Szczechowicz, Marcin
Osswald, Anja
Easo, Jerry
Rad, Arian Arjomandi
Vardanyan, Robert
Schmack, Bastian
Ruhparwar, Arjang
Zhigalov, Konstantin
Weymann, Alexander
author_sort Zubarevich, Alina
collection PubMed
description BACKGROUND: Despite current progress in antibiotic therapy and medical management, infective endocarditis remains a serious condition presenting with high mortality rates. It also is a life-threatening complication in patients with a history of chronic intravenous drug abuse. In this study, we analyzed our institutional experience on the surgical therapy of infective endocarditis in patients with active intravenous drug abuse. The aim of the study is to identify the predictive factors of mortality and morbidity in this subgroup of patients. METHODS: Between 2007 and 2020, a total of 24 patients (7 female, mean age 38.5 ± 8.7) presenting with active intravenous drug abuse underwent a surgical treatment for the infective endocarditis at out center. The primary endpoint was survival at 30th day after the surgery. The secondary composite endpoint included freedom from death, recurrent endocarditis, re-do surgery, and postoperative stroke during the follow-up period. Mean follow-up was 4.2 ± 4.3 years. RESULTS: Staphylococcus species was the most common pathogen detected in the preoperative blood cultures. Infection caused by Enterococcus species as well as liver function impairment were identified as mortality predictor factors. Logistic EuroSCORE and EusoSCORE-II were also predictive factors for mortality in univariate analysis. Survival at 1 and 3 years was 78 and 72% respectively. Thirty-day survival was 88%. 30-day freedom from combined endpoint was 83% and after 1 and 3 years, 69 and 58% of the patients respectively were free from combined endpoint. Five patients (20.8%) were readmitted with recurrent infective endocarditis. CONCLUSION: In patients presenting with active intravenous drug abuse, treatment of infective endocarditis should be performed as aggressively as possible and should be followed by antibiotic therapy to avoid high mortality rates and recurrent endocarditis. Early intervention is advisable in patients with an infective endocarditis and enterococcus species in the preoperative blood cultures, liver function deterioration as well as cardiac function impairment. Attention should be also payed to addiction treatment, due to the elevated relapse rate in patients who actively inject drugs. However, larger prospective studies are necessary to support our results. As septic shock is the most frequent cause of death, new treatment options, e.g. blood purification should be evaluated.
format Online
Article
Text
id pubmed-8056573
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-80565732021-04-20 Surgical treatment of infective endocarditis in intravenous drug abusers Zubarevich, Alina Szczechowicz, Marcin Osswald, Anja Easo, Jerry Rad, Arian Arjomandi Vardanyan, Robert Schmack, Bastian Ruhparwar, Arjang Zhigalov, Konstantin Weymann, Alexander J Cardiothorac Surg Research Article BACKGROUND: Despite current progress in antibiotic therapy and medical management, infective endocarditis remains a serious condition presenting with high mortality rates. It also is a life-threatening complication in patients with a history of chronic intravenous drug abuse. In this study, we analyzed our institutional experience on the surgical therapy of infective endocarditis in patients with active intravenous drug abuse. The aim of the study is to identify the predictive factors of mortality and morbidity in this subgroup of patients. METHODS: Between 2007 and 2020, a total of 24 patients (7 female, mean age 38.5 ± 8.7) presenting with active intravenous drug abuse underwent a surgical treatment for the infective endocarditis at out center. The primary endpoint was survival at 30th day after the surgery. The secondary composite endpoint included freedom from death, recurrent endocarditis, re-do surgery, and postoperative stroke during the follow-up period. Mean follow-up was 4.2 ± 4.3 years. RESULTS: Staphylococcus species was the most common pathogen detected in the preoperative blood cultures. Infection caused by Enterococcus species as well as liver function impairment were identified as mortality predictor factors. Logistic EuroSCORE and EusoSCORE-II were also predictive factors for mortality in univariate analysis. Survival at 1 and 3 years was 78 and 72% respectively. Thirty-day survival was 88%. 30-day freedom from combined endpoint was 83% and after 1 and 3 years, 69 and 58% of the patients respectively were free from combined endpoint. Five patients (20.8%) were readmitted with recurrent infective endocarditis. CONCLUSION: In patients presenting with active intravenous drug abuse, treatment of infective endocarditis should be performed as aggressively as possible and should be followed by antibiotic therapy to avoid high mortality rates and recurrent endocarditis. Early intervention is advisable in patients with an infective endocarditis and enterococcus species in the preoperative blood cultures, liver function deterioration as well as cardiac function impairment. Attention should be also payed to addiction treatment, due to the elevated relapse rate in patients who actively inject drugs. However, larger prospective studies are necessary to support our results. As septic shock is the most frequent cause of death, new treatment options, e.g. blood purification should be evaluated. BioMed Central 2021-04-20 /pmc/articles/PMC8056573/ /pubmed/33879196 http://dx.doi.org/10.1186/s13019-021-01491-1 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research Article
Zubarevich, Alina
Szczechowicz, Marcin
Osswald, Anja
Easo, Jerry
Rad, Arian Arjomandi
Vardanyan, Robert
Schmack, Bastian
Ruhparwar, Arjang
Zhigalov, Konstantin
Weymann, Alexander
Surgical treatment of infective endocarditis in intravenous drug abusers
title Surgical treatment of infective endocarditis in intravenous drug abusers
title_full Surgical treatment of infective endocarditis in intravenous drug abusers
title_fullStr Surgical treatment of infective endocarditis in intravenous drug abusers
title_full_unstemmed Surgical treatment of infective endocarditis in intravenous drug abusers
title_short Surgical treatment of infective endocarditis in intravenous drug abusers
title_sort surgical treatment of infective endocarditis in intravenous drug abusers
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8056573/
https://www.ncbi.nlm.nih.gov/pubmed/33879196
http://dx.doi.org/10.1186/s13019-021-01491-1
work_keys_str_mv AT zubarevichalina surgicaltreatmentofinfectiveendocarditisinintravenousdrugabusers
AT szczechowiczmarcin surgicaltreatmentofinfectiveendocarditisinintravenousdrugabusers
AT osswaldanja surgicaltreatmentofinfectiveendocarditisinintravenousdrugabusers
AT easojerry surgicaltreatmentofinfectiveendocarditisinintravenousdrugabusers
AT radarianarjomandi surgicaltreatmentofinfectiveendocarditisinintravenousdrugabusers
AT vardanyanrobert surgicaltreatmentofinfectiveendocarditisinintravenousdrugabusers
AT schmackbastian surgicaltreatmentofinfectiveendocarditisinintravenousdrugabusers
AT ruhparwararjang surgicaltreatmentofinfectiveendocarditisinintravenousdrugabusers
AT zhigalovkonstantin surgicaltreatmentofinfectiveendocarditisinintravenousdrugabusers
AT weymannalexander surgicaltreatmentofinfectiveendocarditisinintravenousdrugabusers